Cargando…

Bevacizumab Combined with Platinum–Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients

SIMPLE SUMMARY: The OTILIA non-interventional study aimed to assess the safety and effectiveness of a standard treatment regimen for advanced ovarian cancer in Germany. All of the women participating in the study received chemotherapy combined with a targeted treatment called bevacizumab. Among the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sehouli, Jalid, Mustea, Alexander, Oskay-Özcelik, Guelten, Keller, Maren, Richter, Rolf, Tomé, Oliver, Woopen, Hannah, Sommer-Joos, Ann-Katrin, Grabowski, Jacek P., Armbrust, Robert, Wimberger, Pauline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507543/ https://www.ncbi.nlm.nih.gov/pubmed/34638225 http://dx.doi.org/10.3390/cancers13194739

Ejemplares similares

Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group
por: Trillsch, Fabian, et al.
Publicado: (2021)

Results of a German wide survey towards current surgical approach in early stage cervical cancer NOGGO MONITOR 11
por: Armbrust, Robert, et al.
Publicado: (2021)

Impact of health-related quality of life (HRQoL) on short-term mortality in patients with recurrent ovarian, fallopian or peritoneal carcinoma (the NOGGO-AGO QoL Prognosis-Score-Study): results of a meta-analysis in 2209 patients
por: Armbrust, R., et al.
Publicado: (2021)

Corrigendum to ‘Impact of health-related quality of life (HRQoL) on short-term mortality in patients with recurrent ovarian, fallopian or peritoneal carcinoma (the NOGGO-AGO QoL Prognosis-Score-Study): results of a meta-analysis in 2209 patients’: [ESMO Open Volume 6, Issue 2, April 2021, 100081]
por: Richter, R., et al.
Publicado: (2021)

Otilia Rauda /
por: Galindo, Sergio
Publicado: (2013)

Otilia Rauda
por: Galindo, Sergio
Publicado: (1986)

Otilia Rauda /
por: Rotberg, Dana

Otilia Rauda
por: Galindo, Sergio
Publicado: (2001)

Otilia Rauda
por: Galindo, Sergio
Publicado: (2019)

Otilia Rauda
por: Galindo, Sergio
Publicado: (2019)

Current Treatment Practices and Prognostic Factors in Early-Stage Ovarian Cancer—An Analysis of the NOGGO/JAGO
por: Heublein, Sabine, et al.
Publicado: (2023)

El enigma de Otilia
por: Calinescu, George, 1899-1965
Publicado: (1967)

L'énigme d'Otilia : roman
por: Calinescu, George, 1899-1965
Publicado: (1950)

Influence of migrant background on patient preference and expectations in breast and gynecological malignancies (NOGGO-expression V study): results of a prospective multicentre study in 606 patients in Germany
por: Dimitrova, D., et al.
Publicado: (2021)

Otilia Rauda :una lectura desde los personajes y la relación con sus cuerpos/
por: Balderas Chacón, Tania
Publicado: (2011)

Erotismo y transgresión en Otilia Rauda
por: García Alba, Pompeya Elvira
Publicado: (2006)

Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer
por: Liu, Ying, et al.
Publicado: (2015)

A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO)
por: Sehouli, Jalid, et al.
Publicado: (2016)

Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study
por: Runnebaum, Ingo B., et al.
Publicado: (2018)

Current trends in diagnostic and therapeutic management of the axilla in breast cancer patients receiving neoadjuvant therapy: results of the German-wide NOGGO MONITOR 24 survey
por: Banys-Paluchowski, Maggie, et al.
Publicado: (2022)

Side Effects from Cancer Therapies and Perspective of 1044 Long-Term Ovarian Cancer Survivors—Results of Expression VI–Carolin Meets HANNA–Holistic Analysis of Long-Term Survival with Ovarian Cancer: The International NOGGO, ENGOT, and GCIG Survey
por: Woopen, Hannah, et al.
Publicado: (2023)

Hypersensitivity Reactions to Platinum Agents and Taxanes
por: Tsao, Lulu R., et al.
Publicado: (2021)

Real-World Evidence: How Long Do Our Patients Fast?—Results from a Prospective JAGO-NOGGO-Multicenter Analysis on Perioperative Fasting in 924 Patients with Malignant and Benign Gynecological Diseases
por: Beck, Maximilian Heinz, et al.
Publicado: (2023)

Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer
por: Woopen, Hannah, et al.
Publicado: (2014)

Platinum drugs and taxanes: can we overcome resistance?
por: Sazonova, Elena V., et al.
Publicado: (2021)

Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ)
por: Chekerov, Radoslav, et al.
Publicado: (2023)

Effects of sarcopenia and malnutrition on morbidity and mortality in gynecologic cancer surgery: results of a prospective study
por: Sehouli, Jalid, et al.
Publicado: (2021)

Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HR-QoL) in Patients with Ovarian Cancer: What Is Different Compared to Healthy Women?
por: Inci, Melisa Guelhan, et al.
Publicado: (2021)

ECOG and BMI as preoperative risk factors for severe postoperative complications in ovarian cancer patients: results of a prospective study (RISC-GYN—trial)
por: Inci, Melisa Guelhan, et al.
Publicado: (2021)

Preoperative quality of life as prediction for severe postoperative complications in gynecological cancer surgery: results of a prospective study
por: Sehouli, Jalid, et al.
Publicado: (2020)

Correction to: Preoperative quality of life as prediction for severe postoperative complications in gynecological cancer surgery: results of a prospective study
por: Sehouli, Jalid, et al.
Publicado: (2021)

Preference of elderly patients’ to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial
por: Chekerov, Radoslav, et al.
Publicado: (2017)

Sentinel Lymph Node Staging with Indocyanine Green for Patients with Cervical Cancer: The Safety and Feasibility of Open Approach Using SPY-PHI Technique
por: Muallem, Mustafa Zelal, et al.
Publicado: (2021)

Primary Treatment Results in Patients with Ovarian, Fallopian or Peritoneal Cancer—Results of a Clinical Cancer Registry Database Analysis in Germany
por: Armbrust, Robert, et al.
Publicado: (2022)

Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms
por: Imai, Satoshi, et al.
Publicado: (2017)

The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer: an updated systematic review and meta-analysis
por: Ruan, Guanyu, et al.
Publicado: (2018)

Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation
por: Willing, Eva-Maria, et al.
Publicado: (2023)

Survival analysis of bevacizumab plus taxane treatment in luminal metastatic breast cancer
por: Murillo, Serafin Morales, et al.
Publicado: (2021)

Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients
por: Gericke, Beate, et al.
Publicado: (2005)

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
por: Kurtz, Jean-Emmanuel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5nvbj0p7age83hm75693jn1piu